Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biologics

- PMLiVE

FDA grants priority review for new Keytruda licence

Merck’s PD-1 drug being assessed for first-line melanoma patients

- PMLiVE

Novartis licenses cancer support drug from Aveo Oncology

Swiss firm buys into drug to alleviate a wasting syndrome that is seen in chronic patients

Roche Basel Switzerland

Roche’s PD-L1 drug shrinks lung tumours

Drug has already showed success in treating certain bladder cancer patients

- PMLiVE

BMS launches Opdivo for lung cancer in UK

Drug to be called ‘Nivolumab BMS’ in the country

- PMLiVE

AZ signs two more deals in cancer immunotherapy

Anglo-Swedish firm pens partnerships with Heptares and Mirati Therapeutics

- PMLiVE

Ebola vaccine completely effective, say researchers

Merck earns plaudits for ‘game-changing’ vaccine

Bristol-Myers Squibb (BMS) building

BMS signs Opdivo combination pact with Kyowa Hakko Kirin 

Rounds off a week of deals in the immunotherapy space for big pharma

- PMLiVE

Merck hopes for another Keytruda with new immunotherapy deal

US firm signs pact with cCAM Biotherapeutics for cancer research

- PMLiVE

Keytruda cleared for melanoma in Europe

Merck’s new PD-1 drug will compete against rival BMS for market share

- PMLiVE

Merck plans expanded filing for Emend this year

Nausea and vomiting therapy more effective than placebo in 1000-patient trial

- PMLiVE

Merck & Co’s diabetes drug Januvia cleared by CV safety trial

Concerns over the DPP-4 inhibitor 'put to bed' by TECOS cardiovascular trial

Gilead Sciences

Humira remains top pharma product, but Sovaldi closes in

AbbVie’s blockbuster may be bumped to second place this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links